Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nycomed GmbH
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.
Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.
Private equity group Blackstone is reportedly near a deal to acquire Takeda's consumer health business in Japan for up to $2.8bn as the Japanese pharma firm continues to shed non-core assets.
- Other Names / Subsidiaries
- Bradley Pharmaceuticals, Guangdong Techpool Bio-Pharma Co., Ltd.